Theravance Biopharma/$TBPH

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Theravance Biopharma

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Ticker

$TBPH
Primary listing

Industry

Pharmaceuticals

Employees

97

ISIN

KYG8807B1068

TBPH Metrics

BasicAdvanced
$531M
-
-$1.19
-0.10
-

What the Analysts think about TBPH

Analyst ratings (Buy, Hold, Sell) for Theravance Biopharma stock.

Bulls say / Bears say

Theravance Biopharma's key product, YUPELRI, achieved net sales of $58.3 million in Q1 2025, marking a 6% year-over-year increase, indicating strong market demand. (gurufocus.com)
TRELEGY, a product in collaboration with GSK, reported global net sales of $854 million in Q1 2025, a 14% rise compared to Q1 2024, showcasing robust growth in the respiratory market. (gurufocus.com)
BTIG analyst Julian Harrison increased the price target on Theravance Biopharma to $24.00, up from $21.00, citing strong TRELEGY sales and future royalty entitlements. (investing.com)
Theravance Biopharma reported a GAAP net loss of $13.6 million in Q1 2025, compared to $11.7 million in Q1 2024, with earnings per share of -$0.27 missing the forecast of -$0.22. (investing.com)
TD Cowen adjusted its outlook on Theravance Biopharma, lowering the price target to $9 from the previous $10, following the company's report of second-quarter financial results, which included a net loss of $17 million. (investing.com)
The completion of the CYPRESS study for ampreloxetine has been delayed, with the last patient enrollment now expected in mid-2025, postponing it from the second half of 2024. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.

TBPH Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

TBPH Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TBPH

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs